Endpoints News

FDA, Moderna at odds over flu vaccine review		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T Wed Th F

11 February, 2026

After years of rough sledding, biotech investors are getting back to work. Join us for a data-driven look at the field’s top VCs and their strategies for 2026. Get your spot now.

presented by

7 Real-World Ways RWE Is Transforming Healthcare

spotlight

'Bat-sh*t crazy': Biopharma leaders unload on regulatory chaos

news

Moderna accuses FDA of shifting trial standard after agency refuses to review flu shot

Exclusive: Sanofi invests in China startup developing molecular glue for sickle cell disease

Upstream Bio says its severe asthma drug delivered positive data in Phase 2 trial

CGT has fresh momentum from new FDA frameworks and pharma deals, but do the latest advances in science, manufacturing, and regulation actually solve the core challenges? We’re asking the hard questions — join us.

endpoints pharma

Isomorphic claims major advance with new AI drug design engine, in 'step change' versus AlphaFold 3

ILiAD’s hot Series B shows vaccine investors are ready to put money where your nose is

AbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fight

Client Engagement Mgr - Life Sciences Strategy & Intelligence

Sedulo Group

United States

Vice President, Drug Metabolism & Pharmacokinetics (DMPK)

C4 Therapeutics

Watertown, MA, USA

Recruit talent with Endpoints Careers

Contact Meg Estacio: mestacio@endpointsnews.com

in case you missed it

Is AstraZeneca on track to meet its $80B revenue target?

•

AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed back

Shanghai's Cascade gets $72M to pursue MASH, obesity and diabetes drugs

News Briefing

Nektar posts one-year eczema success; Pfizer ends malnutrition trial

Hengrui, Kailera push obesity pill ahead on promising mid-stage China data

CSL’s CEO Paul McKenzie exits after rough few years

Gilead’s 2026 Forecast Falls Short of Wall Street’s Expectations

Moderna’s stock is down around 10% premarket Wednesday, after the company disclosed yesterday that the FDA refused to review its mRNA-based flu vaccine. Moderna, in turn, said that the agency is moving the goalposts for its pivotal trial after both parties previously agreed to them. Read more from Max Bayer here.